GlaxoSmithKline and Medicago have initiated late-stage testing of their investigational plant-based adjuvanted coronavirus vaccine that was granted fast track status by the FDA last month. Up to 30,000 health participants will be enrolled in the Phase 3 study that will assess the use of two vaccine doses administered 21 days apart.
GSK, Medicago launch Phase 3 trial for COVID-19 vaccine
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.